Clinical Evidence: What UK Weight Loss Data Reveals
Mounjaro or Wegovy Which Is Better: Understanding the Clinical Evidence
When evaluating Mounjaro or Wegovy which is better based on UK weight loss results, clinical trial data provides the foundation for informed decisions. Wegovy's STEP programme represents one of the most comprehensive weight management study series ever conducted. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021).
The STEP 5 trial demonstrated sustainability, with participants maintaining ~clinically studied weight loss at two years. Meanwhile, Mounjaro's SURMOUNT trials showed impressive results using a different mechanism—dual GIP and GLP-1 receptor activation. However, comparing these trials directly isn't appropriate due to different study designs, populations, and endpoints. Both represent significant advances in prescription-only weight management treatments available through regulated UK pharmacies.
Weight Loss Results UK: Pricing and Treatment Access
Understanding costs helps determine Mounjaro or Wegovy which is better for your budget. Wegovy starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our Intro Duo bundle (0.25mg and 0.5mg) costs £169.99, providing your first 8 weeks of treatment. New customers apply code FIRST40 at checkout, while returning customers use DOSE25.
EverydayMeds offers both treatments through the same streamlined process: a 3-minute clinical assessment, prescriber review (standard 3 working days, express 24 hours available), and next-day cold-chain delivery. Both medications require identical clinical assessments and ongoing monitoring. The choice between them often comes down to individual response patterns, storage preferences, and prescriber recommendations rather than cost differences alone.
Mounjaro or Wegovy Which Is Better: Mechanism Differences
The fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone. It works primarily on brain appetite centres, reducing hunger signals and promoting satiety after smaller meals. Many patients report decreased food cravings and natural portion control.
Mounjaro contains tirzepatide, which activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual approach may offer additional metabolic benefits beyond appetite control. However, both treatments work by fundamentally changing how your body responds to food intake, requiring commitment to dietary changes and increased physical activity for optimal results.
Clinical Trial Evidence: What STEP Studies Revealed
When considering Mounjaro or Wegovy which is better, Wegovy's STEP programme provides robust UK-relevant data. STEP 3 combined Wegovy with intensive behavioural therapy, achieving ~16% average weight loss. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events, earning NICE recommendation TA875.
These results occurred alongside reduced-calorie diets and increased physical activity—not as standalone treatments. Individual results vary significantly, and no treatment ensures specific outcomes. The clinical evidence supports Wegovy as an effective tool within comprehensive weight management programmes supervised by healthcare professionals.
How Wegovy Works in Practice
Wegovy's GLP-1 receptor agonism creates multiple physiological changes that support weight management. It slows gastric emptying, meaning food stays in your stomach longer, promoting lasting fullness. The medication also influences hypothalamic appetite centres, reducing the neurological drive to eat. Additionally, it may decrease reward-seeking behaviour around high-calorie foods, though individual responses vary considerably. The once-weekly injection schedule using Novo Nordisk's FlexTouch pen system ensures consistent medication levels. Most patients find the injection process straightforward after initial training, with rotating injection sites preventing tissue irritation.
EverydayMeds Ordering Process
Accessing either treatment through our GPhC-registered pharmacy (#9012878) follows the same rigorous process. Complete our 3-minute clinical assessment covering medical history, current medications, weight management goals, and lifestyle factors. Our prescribers review applications within 3 working days (24-hour express service available), ensuring appropriate candidate selection for these prescription-only medicines. Once approved, we dispatch via next-day delivery using specialist cold-chain transport maintaining 2-8°C throughout transit. Each package includes comprehensive injection guidance, dose escalation schedules, and ongoing support contact details.
Storage and Practical Considerations
A practical advantage when comparing Mounjaro or Wegovy which is better involves storage requirements. Both require refrigeration at 2-8°C before first use, but Wegovy offers superior travel flexibility—remaining stable for 6 weeks at room temperature below 30°C once removed from the fridge, compared to Mounjaro's 21-day room temperature limit. This makes Wegovy more suitable for extended travel or irregular storage situations. The FlexTouch pen system includes dose confirmation windows and safety features preventing accidental overdosing. Mandatory dose escalation follows a 20-week schedule: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), then 2.4mg maintenance dosing.
UK Weight Loss Results: Real-World Considerations
Beyond asking Mounjaro or Wegovy which is better, UK patients must consider long-term commitment requirements. STEP 1 extension data showed patients regained approximately two-thirds of lost weight within one year of stopping treatment, emphasising that weight management represents a long-term commitment rather than a short-term intervention. Successful outcomes require ongoing lifestyle modifications, regular monitoring, and potentially indefinite treatment continuation.
NICE guidelines recommend both treatments within specialist weight management programmes, acknowledging their role as tools within comprehensive care pathways. Individual tolerance, side effect profiles, and response patterns often matter more than theoretical mechanism differences when determining optimal treatment choices for specific patients.
Making Your Treatment Decision
Rather than definitively answering Mounjaro or Wegovy which is better, both treatments are available from EverydayMeds, and your prescriber can help determine which suits your individual circumstances. Consider factors like travel requirements (storage differences), injection frequency preferences, previous GLP-1 experience, and concurrent medical conditions. Our clinical team evaluates these factors during assessment, ensuring appropriate treatment selection. Start your assessment today using code FIRST40 for new customers, or DOSE25 for returning patients, accessing expert weight management support through our regulated UK pharmacy service.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
